The Nova StatStrip glucose meter FDA update concerns a software behaviour that can attach a glucose result to the wrong patient, even though the measurement itself is accurate. According to a US Food and Drug Administration (FDA) bulletin dated 20 October 2026, Nova Biomedical has warned users of the StatStrip Glucose Hospital Meter System Gen 2.0 that information from a previous barcode scan can remain on screen. We found no FDA update later than that bulletin, so this article reports the 20 October position. It is news reporting and not medical advice.
Nova StatStrip glucose meter FDA update: key takeaways
- Only the StatStrip Gen 2.0 is affected: Model 63685 and Multipack 66739, all firmware versions. The Gen 1.86 meter is not included.
- After a patient ID or quality-control barcode is scanned, the previous scan’s information can remain on screen, so a result may be filed under the wrong patient or QC ID.
- Analytical accuracy of the glucose measurement is not affected, according to Nova.
- As of 5 October 2026, one serious injury and no deaths had been reported.
- The FDA describes the event as the most serious type of recall, which here is a removal.
What the Nova StatStrip glucose meter FDA update says
The bulletin says that when staff scan a patient ID or QC barcode, information from the earlier scan may stay displayed. If the operator does not notice, the glucose result may be recorded against another patient or against the wrong QC entry. Nova advises removing affected meters from use or sale until a software update is available. The company first notified customers on 31 July 2026 and updated its advice on 5 October 2026, according to the information we reviewed. A phased software rollout from November 2026 has been reported.
Why a patient identification error matters in the Nova StatStrip glucose meter FDA update
In hospitals, glucose results guide insulin dosing. If a reading belongs to patient A but is filed under patient B, then patient B could receive insulin that is not needed, or patient A could have a low or high value missed. The FDA identifies the risk as acting on another patient’s result, which could lead to delayed or unnecessary treatment, including inappropriate insulin. Critically ill patients and infants are described as being at higher risk because their glucose levels can change quickly.
Accuracy versus identification in the Nova StatStrip glucose meter FDA update
Clinical laboratories separate analytical error, where the number is wrong, from pre-analytical and post-analytical error, where the sample or result is misattributed. This recall is the second kind. The measurement may be correct but connected to the wrong record. Studies of laboratory errors have long highlighted identification mistakes as a recurring source of harm, which is why barcode scanning is used. Here a software display behaviour undermines that safeguard. That is general background and not a finding about this device.
What hospitals are told in the Nova StatStrip glucose meter FDA update
- Identify Gen 2.0 meters in use, by model and serial information.
- Follow Nova’s instruction to remove affected meters from use until the software update is installed.
- Contact Nova Biomedical in the US on 1(800) 545-6682.
- Report problems to FDA MedWatch.
The FDA publishes recall information on its medical device recalls page. Visit Nova Biomedical for company information.
What is unclear in the Nova StatStrip glucose meter FDA update
The brief for this story spoke of an FDA update. The most recent FDA material we found is the 20 October 2026 bulletin, and we did not find a later one. We also could not confirm the date or scope of the software rollout beyond the reported phased start in November. Readers should check the FDA page and Nova for any newer notice.
Market context from Acumen Research and Consulting
Acumen Research and Consulting’s Self-Monitoring Blood Glucose Devices Market report values the global market at USD 11.7 billion in 2023 and projects USD 20.6 billion by 2032, a CAGR of 6.7% for 2024 to 2032, with North America at 38% and Asia Pacific at 7.5% growth. By our own calculation, that is about 1.8 times the 2023 value. The report mixes continuous and self-monitoring devices, and its CAGR does not fully reconcile with its endpoints, so use it as indicative. It does not cover hospital meters specifically.
Questions clinicians may ask about the Nova StatStrip glucose meter FDA update
How many meters are in the field? Were any results misfiled before the alert? What interim workflow should wards use when meters are removed? The sources do not answer these. See our medical device coverage.
Timeline of the Nova StatStrip glucose meter FDA update
- 31 July 2026: Nova first notifies customers.
- 5 October 2026: updated advice; one serious injury and no deaths reported by this date.
- 20 October 2026: FDA bulletin published.
- November 2026: phased software rollout reported to begin.
General background: point-of-care glucose testing
Hospital point-of-care meters allow nurses to test at the bedside, with results transmitted to patient records. Accurate identification is as important as accurate measurement.
Our analysis of the Nova StatStrip glucose meter FDA update
In our assessment, the Nova StatStrip glucose meter FDA update is a reminder that safe results depend on software as much as chemistry. The lack of deaths reported by early October is reassuring, but one serious injury shows the risk is real.
What is not disclosed about the Nova StatStrip glucose meter FDA update
- Number of meters affected.
- Exact software release dates.
- Details of the reported serious injury.
Risks and caveats
This article relies on the FDA bulletin and company statements as described in public information, not on the full notice. Nothing here is medical advice.
What to watch next
- Software release and installation.
- Any further FDA notice.
- Reports of additional harm.
FAQ
Which meters are affected?
StatStrip Gen 2.0 only: Model 63685 and Multipack 66739.
Is the glucose reading itself wrong?
No, according to Nova; the issue is the result being filed under the wrong patient or QC ID.
Is there a newer FDA update?
We found none after the 20 October 2026 bulletin.
How we reported this: we relied on the FDA bulletin, public regulator and company pages and the Acumen Research and Consulting report cited above. Our calculations are labelled. Last updated 2 November 2026. This is news reporting and not advice.
